[HTML][HTML] Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)
CA de la Rosa, PC Castellanos, M Lázaro-Quintela… - Lung Cancer, 2022 - Elsevier
Objectives To determine the incidence of ALK translocations in patients with
advanced/metastatic NSCLC in Spain, to describe the clinical characteristics of these …
advanced/metastatic NSCLC in Spain, to describe the clinical characteristics of these …
Case report: pathological complete response to neoadjuvant alectinib in a patient with resectable ALK-positive non-small cell lung cancer
Y Hu, S Ren, R Wang, W Han, P Xiao… - Frontiers in …, 2022 - frontiersin.org
Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line
setting of untreated advanced ALK-positive NSCLC and in the second-line setting of …
setting of untreated advanced ALK-positive NSCLC and in the second-line setting of …
Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
D Sun, J Tao, W Yan, J Zhu, H Zhou… - … in Cancer Research …, 2022 - journals.sagepub.com
Background: In non-small cell lung cancer (NSCLC) patients harboring MET mutations, MET-
tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However …
tyrosine kinase inhibitors (TKIs) have been proven to achieve a good response. However …
Genetic correlation of crizotinib efficacy and resistance in ALK-rearranged non-small-cell lung cancer
C Liu, C Liu, J Liao, JC Yin, X Wu, X Zhao, S Sun… - Lung Cancer, 2022 - Elsevier
Objectives Crizotinib remains one of the most commonly used targeted therapies for ALK
fusion-positive patients. However, the mutational profiles and mechanisms of resistance to …
fusion-positive patients. However, the mutational profiles and mechanisms of resistance to …
Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study
K Miyazaki, A Shiba, T Ikeda, Y Higashi, M Aga… - BMC cancer, 2022 - Springer
Background Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces
severe inflammation and a high white blood cell (WBC) count and is associated with poor …
severe inflammation and a high white blood cell (WBC) count and is associated with poor …
The Change in Paradigm for NSCLC Patients with EML4–ALK Translocation
A Bearz, E De Carlo, A Del Conte, M Spina… - International Journal of …, 2022 - mdpi.com
The severe prognosis linked with a lung cancer diagnosis has changed with the discovery of
oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated …
oncogenic molecularly driven subgroups and the use of tailored treatment. ALK-translocated …
[HTML][HTML] Survival after recurrence following surgical resected non-small cell lung cancer: A multicenter, prospective cohort study
T Takenaka, T Yano, K Yamazaki, T Okamoto… - JTCVS open, 2022 - Elsevier
Objectives The optimal treatment for recurrent non–small cell lung cancer (NSCLC) has not
been standardized. In this prospective cohort study, we evaluated post-recurrence survival …
been standardized. In this prospective cohort study, we evaluated post-recurrence survival …
[HTML][HTML] Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic …
D Roelofsen, H van Hove, V Bukkems, F Russel… - Toxicology in Vitro, 2022 - Elsevier
Commercially available physiologically-based pharmacokinetic (PBPK) modeling platforms
increasingly allow estimations of fetal exposure to xenobiotics. We aimed to explore a …
increasingly allow estimations of fetal exposure to xenobiotics. We aimed to explore a …
Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study
J Kang, QM Deng, KC Peng, P Li… - Genes …, 2022 - Wiley Online Library
Anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer (NSCLC)
respond well to ALK tyrosine kinase inhibitors (TKIs), and echinoderm microtubule …
respond well to ALK tyrosine kinase inhibitors (TKIs), and echinoderm microtubule …
[HTML][HTML] Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
AA Bokhari, WY Lai, AT Le, JL Gabre, TP Chuang… - Lung Cancer, 2022 - Elsevier
Introduction Echinoderm microtubule-associated protein-like 4 (EML4)-Anaplastic
Lymphoma Kinase (ALK) rearrangements occur in 3% to 7% of lung adenocarcinomas and …
Lymphoma Kinase (ALK) rearrangements occur in 3% to 7% of lung adenocarcinomas and …